Study conduct,monitoring and data management in a trinational trial: the OPTIMA model

Abstract

The OPTions In Management with Antiretrovirals (OPTIMA) Trial, a collaboration between three governmental agencies in the USA, UK and Canada is a large-scale, multicenter, randomized controlled trial designed to compare the relative efficacy of different therapeutic strategies in HIV disease. The collaboration of three coordinating centers introduced unique data management issues including: a) use of different data systems for managing “country” trial data; b) two-way data transfer between the coordinating centers and the center where OPTIMA data is merged and analysis files are generated; and c) translation of certain data forms (mainly patient completed questionnaires) into French and Spanish. The involvement of three data centers provided a challenge in planning, designing and executing data management procedures in OPTIMA. Processes were implemented to ensure the trial's successful execution at the trinational level, without disregarding countryspecific requirements and regulations. The OPTIMA model required a significant time and resource investment on behalf of all agencies involved, but allowed for autonomy and a sense of joint ownership of data in different countries.

Get full access to this article

View all access options for this article.

References

1. Kyriakides TC , Babiker A , Singer J et al. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA trial. Control Clin Trials 2003; 24: 481–500.

2. Emery S , Abrams DI , Cooper DA et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23: 198–220.

3. Apfel CC , Korttila K , Abdalla M et al. An international multicenter protocol to assess the single and combined benefits of antiemetic interventions in a controlled clinical trial of a 22 22 factorial design (IMPACT). Control Clin Trials 2003; 24: 736–751

4. Dumont J-M on behalf of the MAAS Research Group . Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis. Design, baseline characteristics, and progress of the multi-center anti-atheroma study (MAAS). Control Clin Trials 1993; 14:209–228.

5. Pauwels RA , Busse W , O'Byrne P et al. The inhaled steroid treatment as regular therapy in early asthma (START): rationale and design. Control Clin Trials 2001; 22: 405–419.

6. The Initio Co-ordinating Committee . An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. Control Clin Trials 2002; 22: 160–175.